Center-Authored Papers

Filters: Author is Rowe, Jacob M  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Young Adult
Tallman MS, Kim HT, Montesinos P, Appelbaum FR, de la Serna J, Bennett JM, Deben G, Bloomfield CD, Gonzalez J, Feusner JH et al..  2010.  Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group. Blood. 116(25):5650-9. Abstract
Vidarabine
Smith MR, Neuberg D, Flinn IW, Grever MR, Lazarus HM, Rowe JM, Dewald G, Bennett JM, Paietta EM, Byrd JC et al..  2011.  Incidence of Therapy-related Myeloid Neoplasia after Initial Therapy for CLL with Fludarabine-Cyclophosphamide versus Fludarabine: Long-Term Follow-up of US Intergroup Study E2997.. Blood. 118(3):3525-3527. Abstract
United States
Smith MR, Neuberg D, Flinn IW, Grever MR, Lazarus HM, Rowe JM, Dewald G, Bennett JM, Paietta EM, Byrd JC et al..  2011.  Incidence of Therapy-related Myeloid Neoplasia after Initial Therapy for CLL with Fludarabine-Cyclophosphamide versus Fludarabine: Long-Term Follow-up of US Intergroup Study E2997.. Blood. 118(3):3525-3527. Abstract
Tretinoin
Tallman MS, Kim HT, Montesinos P, Appelbaum FR, de la Serna J, Bennett JM, Deben G, Bloomfield CD, Gonzalez J, Feusner JH et al..  2010.  Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group. Blood. 116(25):5650-9. Abstract
Treatment Outcome
Tallman MS, Kim HT, Montesinos P, Appelbaum FR, de la Serna J, Bennett JM, Deben G, Bloomfield CD, Gonzalez J, Feusner JH et al..  2010.  Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group. Blood. 116(25):5650-9. Abstract
Treatment Failure
Porter DL, Alyea EP, Antin JH, DeLima M, Estey EH, Falkenburg FJH, Hardy N, Kroeger N, Leis J, Levine J et al..  2010.  NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 16(11):1467-503. Abstract
Transplantation, Homologous
Porter DL, Alyea EP, Antin JH, DeLima M, Estey EH, Falkenburg FJH, Hardy N, Kroeger N, Leis J, Levine J et al..  2010.  NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 16(11):1467-503. Abstract
Time Factors
Smith MR, Neuberg D, Flinn IW, Grever MR, Lazarus HM, Rowe JM, Dewald G, Bennett JM, Paietta EM, Byrd JC et al..  2011.  Incidence of Therapy-related Myeloid Neoplasia after Initial Therapy for CLL with Fludarabine-Cyclophosphamide versus Fludarabine: Long-Term Follow-up of US Intergroup Study E2997.. Blood. 118(3):3525-3527. Abstract
Telomere Homeostasis
Baljevic M, Dumitriu B, Lee J-W, Paietta EM, Wiernik PH, Racevskis J, Chen C, Stein EM, Gallagher RE, Rowe JM et al..  2016.  Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia.. Acta haematologica. 136(4):210-218. Abstract
TELOMERASE
Baljevic M, Dumitriu B, Lee J-W, Paietta EM, Wiernik PH, Racevskis J, Chen C, Stein EM, Gallagher RE, Rowe JM et al..  2016.  Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia.. Acta haematologica. 136(4):210-218. Abstract
Survival Rate
Baljevic M, Dumitriu B, Lee J-W, Paietta EM, Wiernik PH, Racevskis J, Chen C, Stein EM, Gallagher RE, Rowe JM et al..  2016.  Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia.. Acta haematologica. 136(4):210-218. Abstract
Tallman MS, Kim HT, Montesinos P, Appelbaum FR, de la Serna J, Bennett JM, Deben G, Bloomfield CD, Gonzalez J, Feusner JH et al..  2010.  Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group. Blood. 116(25):5650-9. Abstract
September 2011
Smith MR, Neuberg D, Flinn IW, Grever MR, Lazarus HM, Rowe JM, Dewald G, Bennett JM, Paietta EM, Byrd JC et al..  2011.  Incidence of Therapy-related Myeloid Neoplasia after Initial Therapy for CLL with Fludarabine-Cyclophosphamide versus Fludarabine: Long-Term Follow-up of US Intergroup Study E2997.. Blood. 118(3):3525-3527. Abstract
Armand P, Kim HT, Zhang M-J, Perez WS, Dal Cin PS, Klumpp TR, Waller EK, Litzow MR, Liesveld JL, Lazarus HM et al..  2012.  Classifying Cytogenetics in Patients with Acute Myelogenous Leukemia in Complete Remission Undergoing Allogeneic Transplantation: A Center for International Blood and Marrow Transplant Research Study.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 18(2):280-288. Abstract
RNA
Baljevic M, Dumitriu B, Lee J-W, Paietta EM, Wiernik PH, Racevskis J, Chen C, Stein EM, Gallagher RE, Rowe JM et al..  2016.  Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia.. Acta haematologica. 136(4):210-218. Abstract
Remission Induction
Tallman MS, Kim HT, Montesinos P, Appelbaum FR, de la Serna J, Bennett JM, Deben G, Bloomfield CD, Gonzalez J, Feusner JH et al..  2010.  Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group. Blood. 116(25):5650-9. Abstract
RECURRENCE
Porter DL, Alyea EP, Antin JH, DeLima M, Estey EH, Falkenburg FJH, Hardy N, Kroeger N, Leis J, Levine J et al..  2010.  NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 16(11):1467-503. Abstract
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Porter DL, Alyea EP, Antin JH, DeLima M, Estey EH, Falkenburg FJH, Hardy N, Kroeger N, Leis J, Levine J et al..  2010.  NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 16(11):1467-503. Abstract
Polymorphism, Genetic
Baljevic M, Dumitriu B, Lee J-W, Paietta EM, Wiernik PH, Racevskis J, Chen C, Stein EM, Gallagher RE, Rowe JM et al..  2016.  Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia.. Acta haematologica. 136(4):210-218. Abstract
Oncogene Proteins, Fusion
Baljevic M, Dumitriu B, Lee J-W, Paietta EM, Wiernik PH, Racevskis J, Chen C, Stein EM, Gallagher RE, Rowe JM et al..  2016.  Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia.. Acta haematologica. 136(4):210-218. Abstract
Neoplasms, Second Primary
Smith MR, Neuberg D, Flinn IW, Grever MR, Lazarus HM, Rowe JM, Dewald G, Bennett JM, Paietta EM, Byrd JC et al..  2011.  Incidence of Therapy-related Myeloid Neoplasia after Initial Therapy for CLL with Fludarabine-Cyclophosphamide versus Fludarabine: Long-Term Follow-up of US Intergroup Study E2997.. Blood. 118(3):3525-3527. Abstract
Neoplasm Recurrence, Local
Tallman MS, Kim HT, Montesinos P, Appelbaum FR, de la Serna J, Bennett JM, Deben G, Bloomfield CD, Gonzalez J, Feusner JH et al..  2010.  Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group. Blood. 116(25):5650-9. Abstract
Porter DL, Alyea EP, Antin JH, DeLima M, Estey EH, Falkenburg FJH, Hardy N, Kroeger N, Leis J, Levine J et al..  2010.  NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 16(11):1467-503. Abstract
Multiple Myeloma
Porter DL, Alyea EP, Antin JH, DeLima M, Estey EH, Falkenburg FJH, Hardy N, Kroeger N, Leis J, Levine J et al..  2010.  NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 16(11):1467-503. Abstract
Middle Aged
Baljevic M, Dumitriu B, Lee J-W, Paietta EM, Wiernik PH, Racevskis J, Chen C, Stein EM, Gallagher RE, Rowe JM et al..  2016.  Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia.. Acta haematologica. 136(4):210-218. Abstract